Table 1. Open in new tab Demographic and...

Characteristic

With endoscopic
follow-up
[n = 337]

KA group
[n = 91]

CA group
[n = 246]

p-value

Age, year

35.0 [27.0-47.0]

37.0 [29.0-48.0]

34.0 [26.0-47.0]

0.303

BMI, kg/m²

21.4 [19.2-24.3]

21.5 [19.3-24.9]

21.3 [19.1-24.2]

0.465

Sex, n [%]

0.002

Men

147 [43.6]

52 [57.1]

95 [38.6]

Women

190 [56.4]

39 [42.9]

151 [61.4]

ASA score, n [%]

0.050

107 [32.6]

21 [23.1]

86 [36.3]

207 [63.1]

67 [73.6]

140 [59.1]

14 [4.3]

3 [3.3]

11 [4.6]

Hypertension, n [%]

17 [5.0]

6 [6.6]

11 [4.5]

0.412

Preoperative weight loss > 10%, n [%]

91 [27.1]

18 [20.0]

73 [29.7]

0.077

Diabetes mellitus, n [%]

4 [1.2]

3 [3.3]

1 [0.4]

0.062

Smoking status, n [%]

87 [26.0]

28 [30.8]

59 [24.3]

0.229

Previous resection, n [%]

79 [23.6]

18 [19.8]

61 [25.0]

0.317

Associated perianal CD, n [%]

54 [16.1]

21 [23.1]

33 [13.5]

0.034

Disease behaviour,^an [%]

139 [41.4]

41 [45.0]

98 [40.0]

0.403

230 [68.5]

67 [73.6]

163 [66.5]

0.214

122 [36.4]

45 [50.0]

77 [31.4]

0.002

Intolerance to drug treatment, n [%]

8 [2.4]

4 [4.4]

4 [1.6]

0.219

Previous CD treatment, n [%]

Mesalazine

56 [16.7]

31 [34.1]

25 [10.2]

<0.001

Budesonide

93 [29.1]

54 [60.0]

39 [17.0]

<0.001

Thiopurin

127 [37.8]

54 [59.3]

73 [29.8]

<0.001

Methotrexate

28 [8.3]

17 [18.7]

11 [4.5]

<0.001

Anti TNF therapy

182 [54.2]

62 [68.1]

120 [49.0]

0.002

Ustekinumab

26 [7.7]

22 [24.2]

4 [1.6]

<0.001

Vedolizumab

13 [3.9]

9 [9.9]

4 [1.6]

0.002

Postoperative CD treatment, n [%]

Mesalazine

14 [4.3]

0 [0]

14 [5.9]

0.014

Thiopurine

63 [19.2]

10 [11.0]

53 [22.4]

0.019

Methotrexate

12 [3.7]

6 [6.6]

6 [2.5]

0.100

Infliximab

35 [10.7]

28 [11.8]

7 [7.8]

0.292

Adalimumab

62 [18.9]

38 [16.0]

24 [26.4]

0.032

Vedolizumab

10 [3.1]

4 [1.6]

6 [6.7]

0.026

Table 1.

Open in new tab

Demographic and clinical characteristics of patients who underwent ileocolonic resection for Crohn’s disease [CD] with Kono-S anastomosis [KA] and conventional side-to-side anastomosis [CA], and with endoscopic follow-up.

Characteristic	With endoscopic follow-up [n = 337]	KA group [n = 91]	CA group [n = 246]	p-value
Age, year	35.0 [27.0-47.0]	37.0 [29.0-48.0]	34.0 [26.0-47.0]	0.303
BMI, kg/m²	21.4 [19.2-24.3]	21.5 [19.3-24.9]	21.3 [19.1-24.2]	0.465
Sex, n [%]				0.002
Men	147 [43.6]	52 [57.1]	95 [38.6]
Women	190 [56.4]	39 [42.9]	151 [61.4]
ASA score, n [%]				0.050
1	107 [32.6]	21 [23.1]	86 [36.3]
2	207 [63.1]	67 [73.6]	140 [59.1]
3	14 [4.3]	3 [3.3]	11 [4.6]
Hypertension, n [%]	17 [5.0]	6 [6.6]	11 [4.5]	0.412
Preoperative weight loss > 10%, n [%]	91 [27.1]	18 [20.0]	73 [29.7]	0.077
Diabetes mellitus, n [%]	4 [1.2]	3 [3.3]	1 [0.4]	0.062
Smoking status, n [%]	87 [26.0]	28 [30.8]	59 [24.3]	0.229
Previous resection, n [%]	79 [23.6]	18 [19.8]	61 [25.0]	0.317
Associated perianal CD, n [%]	54 [16.1]	21 [23.1]	33 [13.5]	0.034
Disease behaviour,^an [%]
B1	139 [41.4]	41 [45.0]	98 [40.0]	0.403
B2	230 [68.5]	67 [73.6]	163 [66.5]	0.214
B3	122 [36.4]	45 [50.0]	77 [31.4]	0.002
Intolerance to drug treatment, n [%]	8 [2.4]	4 [4.4]	4 [1.6]	0.219
Previous CD treatment, n [%]
Mesalazine	56 [16.7]	31 [34.1]	25 [10.2]	<0.001
Budesonide	93 [29.1]	54 [60.0]	39 [17.0]	<0.001
Thiopurin	127 [37.8]	54 [59.3]	73 [29.8]	<0.001
Methotrexate	28 [8.3]	17 [18.7]	11 [4.5]	<0.001
Anti TNF therapy	182 [54.2]	62 [68.1]	120 [49.0]	0.002
Ustekinumab	26 [7.7]	22 [24.2]	4 [1.6]	<0.001
Vedolizumab	13 [3.9]	9 [9.9]	4 [1.6]	0.002
Postoperative CD treatment, n [%]
Mesalazine	14 [4.3]	0 [0]	14 [5.9]	0.014
Thiopurine	63 [19.2]	10 [11.0]	53 [22.4]	0.019
Methotrexate	12 [3.7]	6 [6.6]	6 [2.5]	0.100
Infliximab	35 [10.7]	28 [11.8]	7 [7.8]	0.292
Adalimumab	62 [18.9]	38 [16.0]	24 [26.4]	0.032
Vedolizumab	10 [3.1]	4 [1.6]	6 [6.7]	0.026

Characteristic	With endoscopic follow-up [n = 337]	KA group [n = 91]	CA group [n = 246]	p-value
Age, year	35.0 [27.0-47.0]	37.0 [29.0-48.0]	34.0 [26.0-47.0]	0.303
BMI, kg/m²	21.4 [19.2-24.3]	21.5 [19.3-24.9]	21.3 [19.1-24.2]	0.465
Sex, n [%]				0.002
Men	147 [43.6]	52 [57.1]	95 [38.6]
Women	190 [56.4]	39 [42.9]	151 [61.4]
ASA score, n [%]				0.050
1	107 [32.6]	21 [23.1]	86 [36.3]
2	207 [63.1]	67 [73.6]	140 [59.1]
3	14 [4.3]	3 [3.3]	11 [4.6]
Hypertension, n [%]	17 [5.0]	6 [6.6]	11 [4.5]	0.412
Preoperative weight loss > 10%, n [%]	91 [27.1]	18 [20.0]	73 [29.7]	0.077
Diabetes mellitus, n [%]	4 [1.2]	3 [3.3]	1 [0.4]	0.062
Smoking status, n [%]	87 [26.0]	28 [30.8]	59 [24.3]	0.229
Previous resection, n [%]	79 [23.6]	18 [19.8]	61 [25.0]	0.317
Associated perianal CD, n [%]	54 [16.1]	21 [23.1]	33 [13.5]	0.034
Disease behaviour,^an [%]
B1	139 [41.4]	41 [45.0]	98 [40.0]	0.403
B2	230 [68.5]	67 [73.6]	163 [66.5]	0.214
B3	122 [36.4]	45 [50.0]	77 [31.4]	0.002
Intolerance to drug treatment, n [%]	8 [2.4]	4 [4.4]	4 [1.6]	0.219
Previous CD treatment, n [%]
Mesalazine	56 [16.7]	31 [34.1]	25 [10.2]	<0.001
Budesonide	93 [29.1]	54 [60.0]	39 [17.0]	<0.001
Thiopurin	127 [37.8]	54 [59.3]	73 [29.8]	<0.001
Methotrexate	28 [8.3]	17 [18.7]	11 [4.5]	<0.001
Anti TNF therapy	182 [54.2]	62 [68.1]	120 [49.0]	0.002
Ustekinumab	26 [7.7]	22 [24.2]	4 [1.6]	<0.001
Vedolizumab	13 [3.9]	9 [9.9]	4 [1.6]	0.002
Postoperative CD treatment, n [%]
Mesalazine	14 [4.3]	0 [0]	14 [5.9]	0.014
Thiopurine	63 [19.2]	10 [11.0]	53 [22.4]	0.019
Methotrexate	12 [3.7]	6 [6.6]	6 [2.5]	0.100
Infliximab	35 [10.7]	28 [11.8]	7 [7.8]	0.292
Adalimumab	62 [18.9]	38 [16.0]	24 [26.4]	0.032
Vedolizumab	10 [3.1]	4 [1.6]	6 [6.7]	0.026

Continuous variables are reported as medians [interquartile range].

BMI, body mass index; ASA, American Society of Anesthesiologists; TNF, tumour necrosis factor; CD, Crohn’s disease.

^aAccording to Montreal classification.

This Feature Is Available To Subscribers Only